Why is Beryl Drugs falling/rising?

As of 11-Aug, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at 18.39, which reflects a decrease of 0.96 or 4.96%. The stock has underperformed its sector by 5.87% today and has been on a consecutive downward trend for the past seven days, resulting in a total decline of 13.3% during this period. Over the last week, the stock has seen a significant drop of 12.01%, and its performance over the past month shows a decrease of 15.06%. Despite a very attractive valuation indicated by a Return on Capital Employed (ROCE) of 11, the stock's profits have fallen by 37% over the past year, contributing to its negative performance. Additionally, the stock is trading below all key moving averages, which suggests a bearish trend.
In the broader market context, Beryl Drugs' performance contrasts sharply with the benchmark, as the Sensex has only declined by 0.51% over the past week and 2.30% over the past month. The stock's year-to-date performance shows a staggering drop of 49.13%, while the benchmark has increased by 3.15%. This significant underperformance indicates weak long-term fundamental strength, with a poor EBIT to Interest ratio of 0.86 and slow growth in net sales and operating profit over the last five years. The majority of shareholders being non-institutional may also reflect a lack of confidence in the stock, further exacerbating its decline.